HK Stock MarketDetailed Quotes

02269 WUXI BIO

Watchlist
  • 14.300
  • +0.540+3.92%
Market Closed Mar 28 16:08 CST
60.90BMarket Cap16.23P/E (TTM)

About WUXI BIO Company

The Group is the world's leading open biopharmaceutical technology platform company, providing end-to-end solutions for the discovery, development and production of biopharmaceuticals. Biopharmaceuticals are a subclassification of pharmaceuticals that have revolutionized the treatment of diseases in many major treatment fields around the world. The Group's end-to-end service platform enables it to provide services covering the entire biopharmaceutical development process and to provide customers with customized solutions according to their individual service requirements at any stage of the biopharmaceutical development process. The biopharmaceutical development process generally covers five stages: (i) drug discovery, (ii) preclinical development, (iii) early (phase I and II) clinical development, (iv) late stage (phase III) clinical development, and (v) commercial production. The services required for the biopharmaceutical development process can be divided into two categories: (1) pre-IND services, which include services provided in the first two stages of the biopharmaceutical development process, and (2) post-IND services, which include services provided in the remaining three stages of the biopharmaceutical development process. The Group's business model is based on its “follow the molecule” and “win the molecule” strategy. Customer demand for the Group's services will generally increase as their biopharmaceuticals advance through the biopharmaceutical development process and eventually commercialize production. As a result, the Group's revenue from each integrated project usually also increases as the project progresses.

Company Profile

Symbol02269
Company NameWUXI BIO
ISINKYG970081173
Listing Date06/13/2017
Issue Price20.60
Shares Offered192.98M share
Founded02/27/2014
RegistrationCayman Islands
ChairmanGe Li
SecretaryYue\cenyingwen Huang
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficePO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of Business5/F, Manulife Plaza, 348 Kwun Tong Road, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees17172
MarketHong Kong motherboard
Phone(86)51085353482
Emailinfo@wuxibiologics.com
Business Yaoming Biotechnology Co., Ltd. is an investment holding company that mainly provides biologics discovery, development and production services. The company provides one-stop, end-to-end biopharmaceutical services through an integrated biopharmaceutical contract research, development and production organization (CRDMO) platform. The stages of the biopharmaceutical development process include pre-IND (drug discovery, pre-clinical development), early (phase I and II) clinical development, late stage (phase III) clinical development and commercial production. The company also provides end-to-end CRDMO services for vaccines, including vaccine discovery and development, scale-up of commercial production, and global distribution. The company has the WuxiBody bispecific antibody technology platform, the SDARbody multi-specific antibody technology platform, the WuxiUP continuous production platform, and the mRNA vaccine platform. The company mainly operates in domestic and overseas markets in China.

Company Executives

  • Name
  • Position
  • Salary
  • Zhisheng Chen
  • Authorized Representative,CEO,Executive Director
  • --
  • Weichang Zhou
  • Senior VP,chief technology officer,Executive Director
  • --
  • Ge Li
  • Non-Executive Director,Chairman,Nomination Committee Chairman
  • --
  • Yibing Wu
  • Non-Executive Director
  • --
  • Yanling Cao
  • Non-Executive Director
  • --
  • William Robert Keller
  • Nomination Committee Member,Independent Non-Executive Director,Audit Committee Member,Remuneration Committee Chairman
  • --
  • Kenneth Walton Hitchner III
  • Independent Non-Executive Director,Audit Committee Member,Remuneration Committee Member
  • --
  • Guoliang Dai
  • Independent Non-Executive Director,Remuneration Committee Member,Nomination Committee Member,Audit Committee Chairman
  • --
  • Jue Chen
  • Independent Non-Executive Director
  • --
  • Ming Tu
  • Co-Chief Financial Officer
  • --
  • Jijie Gu
  • Chief Scientific Officer,Executive VP
  • --
  • Jian Dong
  • VP
  • --
  • Xuejian Xu
  • Senior VP,Chief Quality Officer
  • --
  • Keqiang Shen
  • Senior Vice President and Supervisor of China Biotech Manufacturing
  • --
  • William Aitchison
  • Senior Vice President of Global Manufacturing
  • --
  • Angus Scott Marshall Turner
  • VP
  • --
  • Yingwen Cen
  • Joint Company Secretary,Authorized Representative
  • --
  • Yue Huang
  • Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg